Reuters logo
TEXT-S&P: Royalty Pharma rating unaffected by loan repricing
September 26, 2012 / 3:10 PM / 5 years ago

TEXT-S&P: Royalty Pharma rating unaffected by loan repricing

Sept 26 - Standard & Poor's Ratings Services said today that its 'BBB-'
corporate credit rating on New York City-based RPI Finance Trust remains
unchanged following a repricing of its credit facility.

Our ratings on RPI Finance Trust reflect a "satisfactory" business risk 
profile, shown by management's solid track record in conducting acquisitions 
that have resulted in a diverse, high-quality portfolio of royalty-generating 
pharmaceutical assets with solid sales growth prospects. The company's 
"significant" financial risk profile reflects our belief that RPI will 
continue its aggressive acquisition pace, but maintain a financial policy that 
keeps leverage at no more than 4x.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below